Methamphetamine: adverse event reports filed with FDA

9,189

reports as suspect product

0% of all reports · about 424 a year

1,588

reports, 12 months to June 2026

1,474 in the 12 months before

93.6%

marked serious by the reporter

57.4% across all reports

69.9%

record death among outcomes, as reported

6,420 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Methamphetamine reports recording the termall reports in the database

1. Drug abusemisuse of a medicine50.6%4,653
2. Toxicity to various agentspoisoning or toxic effect of one or more substances23.6%2,169
3. Drug diversion8.2%757
4. Deaththe patient died; cause not stated by this term7%646
5. Completed suicidedeath by suicide6.1%558
6. Overdosea dose above the recommended amount5.1%472
7. Drug dependencedependence on a medicine3.9%354
8. Cardiac arrestthe heart stopped3.3%307
9. Drug screen positive3.3%304
10. Substance abuse3.1%284
11. Cardio-respiratory arrestthe heart and breathing stopped3.1%282
12. Respiratory arrestbreathing stopped2.5%230
13. Impaired driving ability2.3%207
14. Road traffic accidenta road accident1.9%173
15. Foetal exposure during pregnancythe unborn baby was exposed to the medicine1.4%133
16. Homicide1.4%126
17. Intentional product misusedeliberate use not as intended1.3%123
18. Poisoning1.3%122
19. Prescription drug used without a prescription1.3%122
20. Maternal exposure during pregnancythe mother took the medicine during pregnancy1.3%118
21. Drug withdrawal syndromesymptoms on stopping a medicine1.3%115
22. Drug interactionan interaction between medicines1.2%114
23. Substance use disorder1.2%112
24. Accidental overdosean accidental overdose1.1%98
25. Aggressionaggressive behaviour1%96
26. Coma1%91
27. Incorrect route of product administrationthe product was given by the wrong route1%91
28. Loss of consciousnesspassing out0.9%85
29. Unresponsive to stimuli0.9%80
30. Product counterfeit0.8%78

Top 30 of 691 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 86.1% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 9,189 reports.

Drugs most often listed in the same reports

Other products listed in reports where Methamphetamine is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Methamphetamine as a suspect or interacting product; reports listing it only as a concomitant medication (574) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.